Association between cancer and immunosuppressive therapy - Analysis of selected studies in pemphigus and pemphigoid

Annals of Pharmacotherapy

Volumn 44, Issue 11, 2010, Pages 1770-1776

  Mabrouk, Dalia ^a   Gürcan, Hakan M ^a   Keskin, Derin B ^b   Christen, William G ^c,d   Ahmed, A Razzaque ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Immunosuppressive agents; Pemphigoid; Pemphigus

Indexed keywords

AZATHIOPRINE; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CECUM CANCER; DRUG EFFECT; DRUG USE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARYNX CARCINOMA; LEUKEMIA; LUNG CANCER; NEOPLASM; OVARY CANCER; PANCREAS CANCER; PEMPHIGOID; PEMPHIGUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN CANCER; STOMACH CANCER; UTERUS CANCER;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; PEMPHIGOID, BULLOUS; PEMPHIGUS; RETROSPECTIVE STUDIES;

EID: 78049474725     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P309     Document Type: Review

References (55)

1. Zillikens D. Diagnosis of autoimmune bullous skin diseases. Clin Lab 2008;54:491-503.
2. Ahmed AR. Recent advances in the treatment of autoimmune mucocutaneous blistering diseases. Int J Periodontics Restorative Dent 2007;27: 309-10.
3. Korman NJ. New immunomodulating drugs in autoimmune blistering diseases. Dermatol Clin 2001;19:637-48.
4. Ahmed AR, Chu TM, Provost TT. Bullous pemphigoid: clinical and serologic evaluation for associated malignant neoplasms. Arch Dermatol 1977;113:96-9.
5. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown and Company, 1987.
6. Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008;115:2146-52
7. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003;149:138-45.
8. Olszewska M, Kolacinska-Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol 2007;8:85-92.
9. Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003;49:276-80.
10. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 1987;16:527-33.
11. Lamey PJ, Rees TD, Binnie WH. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol 1992;74:54-7.
12. Linton WT, Craig GE. Pemphigus: a comparison of the results of treatment at the Royal Victoria Hospital, Montreal, in the steroid and presteroid eras. Can Med Assoc J 1961;85:1192-4.
13. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate and heparin. Acta Derm Venereol 1988;68:413-21.
14. Fernandes NC, Perez M. Treatment of pemphigus vulgaris and pemphigus folliaceus: experience with 71 patients over a 20-year period. Rev Inst Med Trop S Paulo 2001;43:33-6.
15. Lever WF, White H. Treatment of pemphigus with corticosteroids: results obtained in 46 patients over a period of 11 years. Arch Dermatol 1963;87:12-26.
16. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976;112:962-70.
17. Costello MJ, Jaimovich L, Dannenberg M. Treatment of pemphigus with corticosteroids; study of fifty-two patients. JAMA 1957;165:1249-55.
18. Sanders SL, Brodey M, Nelson CT. Corticosteroid treatment of pemphigus. Experience with fifty cases over a period of ten years. Arch Dermatol 1960;82:717-24.
19. Church R. Pemphigoid treated with corticosteroids. Br J Dermatol 1960; 72:434-8.
20. Nelson CT, Brodey M. Cortisone and corticotropin treatment of pemphigus; experience with twenty-eight cases over a period of five years. AMA Arch Derm 1955;72:495-505.
21. Perry H. Pemphigus folliaceus. Arch Dermatol 1961;83:52-72.
22. Stevenson CJ. Treatment in bullous diseases with corticosteroid drugs and corticotrophin. Br J Dermatol 1960;72:11-21.
23. Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009;161:723-31.
24. National Cancer Institute. http://seer.cancer.gov/csr/1975-2006/browse- csr.php (accessed 2010 Mar 29).
25. Terhorst D, Drecoll U, Stockfleth El, Ulrich C. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol 2009;161:85-9.
26. Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid organ transplant among elderly adults. Int J Cancer 2010;126:1724-31.
27. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001;357:1850-1.
28. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 2003;82:177-86.
29. Malik M, Gürcan HM, Christen W, Ahmed AR. Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin. J Oral Pathol Med 2007;36:1-5.
30. Letko E, Gürcan HM, Papaliodis GN, et al. Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the beta4 integrin subunit. Clin Exp Dermatol 2007;32:637-41.
31. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004;9:29-33.
32. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358: 1042-5.
33. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI. The development of b-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992;26:836-40.
34. Watabe H, Soma Y, Obara W, et al. Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm Venereol 2006;86:184-5.
35. Lelièvre JD, Sacre K, Adle-Biassette H, et al. Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol 2005;52:24-7.
36. Lain EL, Markus RF. Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J Drugs Dermatol 2004;3:680-2.
37. Corazza M, Zampino MR, Montanari A, et al. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003;206:330-3.
38. Mahé E, Descamps V, Grossin M, et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003;149:170-3.
39. Fozza C, Dore F, Bonfigli S, et al. Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and waldenstrom macroglobulinemia. Eur J Dermatol 2005;15: 271-3.
40. Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 2005;4:189-94.
41. Zachariae H, Kragballe K, Hansen HE, et al. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136: 531-5.
42. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6.
43. Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8.
44. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17:962-71.
45. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-92.
46. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38:1120-7.
47. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983;42:368-73.
48. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
49. Keysser G, Keysser C, Keysser M. Treatment of refractory rheumatoid arthritis with low dose cyclophosphamide. Long term follow-up of 108 patients. Z Rheumatol 1998;57:101-7.
50. Buchbinder R, Barber M, Heuzenroeder L. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9.
51. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008;168:378-81.
52. Rawoot A, Little F, Heckmann JM. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years. S Afr Med J 2006;96:1249-51.
53. Hohlfeld R, Michels M, Heininger K, Besinger U. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988;38:258-61.
54. Putzki N, Knipp S, Ramczykowski T, et al. Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis. Mult Scler 2006;12:363-6.
55. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46:1607-12.